The company has not disclosed the size of the offering, making it impossible to quantify the dilution. Monitor for a subsequent 8-K or press release disclosing the actual number of shares sold and the gross proceeds. The stockholder approval meeting for the common warrants within 90 days is a key catalyst.
Price Chart
Executive Summary
HCW Biologics entered into a securities purchase agreement on September 23, 2026, to sell shares of common stock, pre-funded warrants, and common stock purchase warrants to accredited investors in a private placement. The offering size, share count, and per-share purchase price are redacted as undisclosed amounts. The common warrants are exercisable at the per-share purchase price for 5.5 years, and the company has agreed to seek stockholder approval for their issuance. The company also entered into a registration rights agreement to register the resale of the securities and imposed a 6-month lock-up on insiders and a 60-day standstill on itself. This is a dilutive capital raise for a clinical-stage biotech company with no disclosed financial results, making the near-term impact bearish due to dilution.
Key Facts
- HCW Biologics entered into a securities purchase agreement on September 23, 2026, to sell shares, pre-funded warrants, and common stock purchase warrants to accredited investors.
- The offering size, share count, and per-share purchase price are redacted as undisclosed amounts.
- Common warrants are exercisable at the per-share purchase price for 5.5 years and represent 100% of the shares and pre-funded warrant shares purchased.
- The company agreed to seek stockholder approval for the issuance of common warrants within 90 days of closing.
- A registration rights agreement was entered into to register the resale of the securities, with a filing deadline of 15 trading days after closing and an effectiveness deadline of 60 days after closing.
- Insiders, including directors, executive officers, and 5%+ holders, are subject to a 6-month lock-up; the company itself has a 60-day standstill after the effective date of the registration statement.
- The company is prohibited from engaging in variable rate transactions, ATM offerings, or other equity issuances until 60 days after the effective date of the initial registration statement.
- Proceeds are to be used for working capital purposes.
Financial Impact
Undisclosed amount of common stock, pre-funded warrants, and common stock purchase warrants sold in a private placement. The common warrants represent 100% of the shares and pre-funded warrant shares purchased, creating significant potential dilution upon exercise.
Risk Factors
- Significant dilution to existing shareholders from the issuance of shares and potential exercise of common warrants.
- The company is a clinical-stage biotech with no disclosed revenue or financial results, increasing the risk profile.
- Failure to obtain stockholder approval for the common warrants could limit the company's ability to issue them.
- The lock-up agreements and standstill may pressure the stock if insiders sell after the lock-up expires.
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001493152-26-044078 |
| Exhibit: ex10-2.htm | 0001493152-26-044078 |
| Exhibit: ex4-2.htm | 0001493152-26-044078 |
| Exhibit: ex4-1.htm | 0001493152-26-044078 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 13, 2026 14d ago | EFFECT | $1.26 | awaiting T+60 | — | $1.10 (+12.70%) |
Oct 2, 2026 24d ago | S-1 | $1.64 | awaiting T+60 | — | $1.10 (+32.93%) |
Oct 1, 2026 26d ago | DEF 14A | $1.69 | awaiting T+60 | — | $1.10 (+34.91%) |
Sep 24, 2026 4w ago | 8-K | $1.99 | awaiting T+60 | — | $1.10 (+44.72%) |
Aug 20, 2026 9w ago | S-1 | $2.12 | awaiting T+60 | — | $1.10 (−48.11%) |
Aug 14, 2026 10w ago | 8-K | $2.68 | awaiting T+60 | — | $1.10 (+58.96%) |
Aug 14, 2026 10w ago | Press Release | $2.68 | awaiting T+60 | — | $1.10 (+58.96%) |
Aug 14, 2026 10w ago | 10-Q/A | $2.68 | awaiting T+60 | — | $1.10 (+58.96%) |
Aug 14, 2026 10w ago | 8-K | $2.68 | awaiting T+60 | — | $1.10 (+58.96%) |
Jul 29, 2026 12w ago | Press Release | $2.58 $1.12 | ▲ +56.59% | ▲ +61.32% | $1.10 (+57.36%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers